Loading...

biote Corp.

BTMDNASDAQ
Healthcare
Medical - Care Facilities
$2.21
$0.10(4.74%)
U.S. Market opens in 1h 28m

biote Corp. Fundamental Analysis

biote Corp. (BTMD) shows moderate financial fundamentals with a PE ratio of 2.51, profit margin of 14.07%, and ROE of -35.31%. The company generates $0.3B in annual revenue with weak year-over-year growth of -2.52%.

Key Strengths

Cash Position35.72%
PEG Ratio0.01

Areas of Concern

ROE-35.31%
We analyze BTMD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 19.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
19.0/100

We analyze BTMD's fundamental strength across five key dimensions:

Efficiency Score

Excellent

BTMD demonstrates superior asset utilization.

ROA > 10%
25.13%

Valuation Score

Excellent

BTMD trades at attractive valuation levels.

PE < 25
2.51
PEG Ratio < 2
0.01

Growth Score

Weak

BTMD faces weak or negative growth trends.

Revenue Growth > 5%
-2.52%
EPS Growth > 10%
8.34%

Financial Health Score

Excellent

BTMD maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.88
Current Ratio > 1
1.22

Profitability Score

Weak

BTMD struggles to sustain strong margins.

ROE > 15%
-3530.97%
Net Margin ≥ 15%
14.07%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BTMD Expensive or Cheap?

P/E Ratio

BTMD trades at 2.51 times earnings. This suggests potential undervaluation.

2.51

PEG Ratio

When adjusting for growth, BTMD's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values biote Corp. at -1.16 times its book value. This may indicate undervaluation.

-1.16

EV/EBITDA

Enterprise value stands at 0.30 times EBITDA. This is generally considered low.

0.30

How Well Does BTMD Make Money?

Net Profit Margin

For every $100 in sales, biote Corp. keeps $14.07 as profit after all expenses.

14.07%

Operating Margin

Core operations generate 18.50 in profit for every $100 in revenue, before interest and taxes.

18.50%

ROE

Management delivers $-35.31 in profit for every $100 of shareholder equity.

-35.31%

ROA

biote Corp. generates $25.13 in profit for every $100 in assets, demonstrating efficient asset deployment.

25.13%

Following the Money - Real Cash Generation

Operating Cash Flow

biote Corp. produces operating cash flow of $50.57M, showing steady but balanced cash generation.

$50.57M

Free Cash Flow

biote Corp. generates strong free cash flow of $43.09M, providing ample flexibility for dividends, buybacks, or growth.

$43.09M

FCF Per Share

Each share generates $0.98 in free cash annually.

$0.98

FCF Yield

BTMD converts 30.83% of its market value into free cash.

30.83%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

2.51

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.008

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.16

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.51

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.88

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.22

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.35

vs 25 benchmark

ROA

Return on assets percentage

0.25

vs 25 benchmark

ROCE

Return on capital employed

0.57

vs 25 benchmark

How BTMD Stacks Against Its Sector Peers

MetricBTMD ValueSector AveragePerformance
P/E Ratio2.5129.88 Better (Cheaper)
ROE-35.31%682.00% Weak
Net Margin14.07%-46037.00% (disorted) Strong
Debt/Equity-1.880.42 Strong (Low Leverage)
Current Ratio1.224.49 Neutral
ROA25.13%-16420.00% (disorted) Strong

BTMD outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews biote Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-60.07%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-77.55%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-67.75%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ